An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma

J Lipid Res. 2008 Mar;49(3):581-7. doi: 10.1194/jlr.M700385-JLR200. Epub 2007 Dec 3.

Abstract

Prebeta1 HDL is the initial plasma acceptor of cell-derived cholesterol in reverse cholesterol transport. Recently, small amphipathic peptides composed of D-amino acids have been shown to mimic apolipoprotein A-I (apoA-I) as a precursor for HDL formation. ApoA-I mimetic peptides have been proposed to stimulate the formation of prebeta1 HDL and increase reverse cholesterol transport in apoE-null mice. The existence of a monoclonal antibody (MAb 55201) and a corresponding ELISA method that is selective for the detection of the prebeta(1) subclass of HDL provides a means of establishing a correlation between apoA-I mimetic dose and prebeta1 HDL formation in human plasma. Using this prebeta1 HDL ELISA, we demonstrate marked apoA-I mimetic dose-dependent prebeta1 HDL formation in human plasma. These results correlated with increases in band density of the plasma prebeta1 HDL, when observed by Western blotting, as a function of increased apoA-I mimetic concentration. Increased prebeta1 HDL formation was observed after as little as 1 min and was maximal within 1 h. Together, these data suggest that a high-throughput prebeta1 HDL ELISA provides a way to quantitatively measure a key component of the reverse cholesterol transport pathway in human plasma, thus providing a possible method for the identification of apoA-I mimetic molecules.

MeSH terms

  • Apolipoprotein A-I*
  • Biological Transport
  • Cholesterol / metabolism
  • Dose-Response Relationship, Drug
  • Enzyme-Linked Immunosorbent Assay
  • High-Density Lipoproteins, Pre-beta / biosynthesis*
  • High-Density Lipoproteins, Pre-beta / drug effects
  • Humans
  • Kinetics
  • Molecular Mimicry
  • Peptides / pharmacology*

Substances

  • Apolipoprotein A-I
  • High-Density Lipoproteins, Pre-beta
  • Peptides
  • Cholesterol